Ginkgo Bioworks

DNANYSE United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$513.435 M

$7.98 +1.27%

Close of 21 Sept 2026

Revenue

$170.2M

#2344 by revenue

Earnings

-$313.0K

Loss-making

Shares outstanding

63,711,102

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#67Autolus TherapeuticsAUTL$516.4M
#68Entera BioENTX$514.5M
#69Ginkgo BioworksDNA$513.4M
#70Eikon TherapeuticsEIKN$478.3M
#71Kyverna TherapeuticsKYTX$440.3M

What if Ginkgo Bioworks were worth as much as…

Open the what-if tool →

Gold $30.3T

$470,530.37

Per share 58,964× higher

Bitcoin $1.72T

$26,729.82

Per share 3,350× higher

Nvidia $5.48T

$85,169.95

Per share 10,673× higher

Or at a round number

$1.00B $2.00B $5.00B $10.0B

Where these numbers come from

Share counts and financials for Ginkgo Bioworks are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.